0.7139USD+2.23%Mkt Cap: 23.78M USDP/E: —Last update: 2026-06-01
Pasithea Therapeutics Corp., a clinical-stage biotechnology company, focuses on the discovery, research, and development of treatments for central nervous system (CNS) disorders, RASopathies, and cancers. Its lead produc…
Industry Peers
Biotechnology111.39BUSDP/E 26.0
100.62BDKKP/E 19.4
62.97BUSDP/E 14.7
48.39BEURP/E 31.7
44.65BEURP/E 37.2
40.10BUSDP/E 75.3
35.22BUSD—
32.91BSEKP/E 48.6
Indicators:|
Key Statistics
Company
Market Cap23.78M USD
Enterprise Value-26.50M USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-20.43M USD
Revenue/Share—
Last Price0.7139 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees5
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-0.71
PEG—
EV/EBITDA1.54
EV/Revenue—
P/S—
P/B0.33
EPS (TTM)-1.42
EPS (Forward)-1.01
52W Range
0.281024% of range2.060
52W High2.060 USD
52W Low0.2810 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-36.99%
ROA-33.91%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-15.21M USD
CapEx (TTM)—
FCF Margin—
FCF Yield-49.78%
Net Debt-50.40M USD
Net Debt/EBITDA2.92
Balance Sheet
Debt/Equity—
Current Ratio35.40
Quick Ratio33.84
Book Value/Sh2.198 USD
Cash/Share1.508 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:20
Split DateJan 2, 2024
Analyst Consensus
Rating1.0 (Strong Buy)
Target (Mean)3.000 USD
Target Range3.000 USD – 3.000 USD
# Analysts1
Ownership
Shares Out.33.41M
Float18.68M
Insiders1.11%
Institutions60.04%
Short Interest
Short Ratio0.7d
Short % Float0.90%
Short % Out.0.89%
Shares Short297.46K
Short (prev mo.)227.97K
Technical
SMA 500.7526 (-5.1%)
SMA 2000.8168 (-12.6%)
Beta0.22
S&P 52W Chg27.94%
Avg Vol (30d)427.26K
Avg Vol (10d)373.43K
Technical Indicators
RSI (14)41.4
MACD-0.0170
MACD Signal-0.0088
MACD Hist.-0.0082
BB Upper0.8852 USD
BB Middle0.7687 USD
BB Lower0.6521 USD
BB Width30.33%
ATR (14)0.0523 USD
Vol Ratio (20d)4.11x